Ami Fadia
Stock Analyst at Needham
(3.71)
# 813
Out of 4,732 analysts
378
Total ratings
48.38%
Success rate
7.65%
Average return
Main Sectors:
Stocks Rated by Ami Fadia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMRX Immuneering | Reiterates: Buy | $15 | $2.02 | +642.57% | 12 | Jan 13, 2025 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Buy | $33 | $12.54 | +163.16% | 18 | Jan 13, 2025 | |
| HRMY Harmony Biosciences Holdings | Reiterates: Buy | $52 | $39.05 | +33.16% | 30 | Jan 13, 2025 | |
| ITCI Intra-Cellular Therapies | Downgrades: Hold | $100 | $126.20 | -20.76% | 26 | Jan 13, 2025 | |
| BCYC Bicycle Therapeutics | Reiterates: Buy | $32 | $13.34 | +139.88% | 16 | Jan 13, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Buy | $133 | $91.94 | +44.67% | 9 | Jan 13, 2025 | |
| BPMC Blueprint Medicines | Reiterates: Buy | $135 | $110.05 | +22.67% | 26 | Jan 13, 2025 | |
| AVDL Avadel Pharmaceuticals | Maintains: Buy | $22 → $19 | $7.75 | +145.16% | 32 | Jan 9, 2025 | |
| NMRA Neumora Therapeutics | Reiterates: Buy | $23 | $2.05 | +1,021.95% | 6 | Jan 2, 2025 | |
| NBIX Neurocrine Biosciences | Reiterates: Hold | n/a | $143.26 | - | 11 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $207 | $121.18 | +70.82% | 26 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $15 | $8.03 | +86.80% | 21 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $85 | $39.45 | +115.46% | 25 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $62 | $40.29 | +53.88% | 20 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $7.08 | - | 18 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $270 | $140.55 | +92.10% | 36 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $17.57 | +59.36% | 6 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $151 | $70.54 | +114.06% | 7 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $16 | $0.56 | +2,767.38% | 2 | Feb 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $63 → $75 | $22.36 | +235.42% | 7 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $23 | $1.54 | +1,361.04% | 4 | Oct 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $64 → $63 | $23.84 | +164.26% | 5 | Sep 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $5 | $3.28 | +52.44% | 2 | Jan 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $21.92 | - | 9 | Oct 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $1.63 | +1,249.69% | 4 | Jan 3, 2018 |
Immuneering
Jan 13, 2025
Reiterates: Buy
Price Target: $15
Current: $2.02
Upside: +642.57%
Day One Biopharmaceuticals
Jan 13, 2025
Reiterates: Buy
Price Target: $33
Current: $12.54
Upside: +163.16%
Harmony Biosciences Holdings
Jan 13, 2025
Reiterates: Buy
Price Target: $52
Current: $39.05
Upside: +33.16%
Intra-Cellular Therapies
Jan 13, 2025
Downgrades: Hold
Price Target: $100
Current: $126.20
Upside: -20.76%
Bicycle Therapeutics
Jan 13, 2025
Reiterates: Buy
Price Target: $32
Current: $13.34
Upside: +139.88%
Axsome Therapeutics
Jan 13, 2025
Reiterates: Buy
Price Target: $133
Current: $91.94
Upside: +44.67%
Blueprint Medicines
Jan 13, 2025
Reiterates: Buy
Price Target: $135
Current: $110.05
Upside: +22.67%
Avadel Pharmaceuticals
Jan 9, 2025
Maintains: Buy
Price Target: $22 → $19
Current: $7.75
Upside: +145.16%
Neumora Therapeutics
Jan 2, 2025
Reiterates: Buy
Price Target: $23
Current: $2.05
Upside: +1,021.95%
Neurocrine Biosciences
Dec 20, 2024
Reiterates: Hold
Price Target: n/a
Current: $143.26
Upside: -
Dec 12, 2024
Reiterates: Buy
Price Target: $207
Current: $121.18
Upside: +70.82%
Dec 11, 2024
Downgrades: Hold
Price Target: $15
Current: $8.03
Upside: +86.80%
Dec 9, 2024
Reiterates: Buy
Price Target: $85
Current: $39.45
Upside: +115.46%
Dec 6, 2024
Maintains: Buy
Price Target: $68 → $62
Current: $40.29
Upside: +53.88%
Nov 20, 2024
Reiterates: Hold
Price Target: n/a
Current: $7.08
Upside: -
Nov 18, 2024
Downgrades: Hold
Price Target: $270
Current: $140.55
Upside: +92.10%
Nov 7, 2024
Reiterates: Buy
Price Target: $28
Current: $17.57
Upside: +59.36%
Nov 7, 2024
Reiterates: Buy
Price Target: $151
Current: $70.54
Upside: +114.06%
Feb 1, 2021
Maintains: Outperform
Price Target: $12 → $16
Current: $0.56
Upside: +2,767.38%
Jan 21, 2021
Downgrades: Market Perform
Price Target: $63 → $75
Current: $22.36
Upside: +235.42%
Oct 1, 2020
Maintains: Market Perform
Price Target: $15 → $23
Current: $1.54
Upside: +1,361.04%
Sep 17, 2020
Maintains: Outperform
Price Target: $64 → $63
Current: $23.84
Upside: +164.26%
Jan 30, 2019
Downgrades: Market Perform
Price Target: $12 → $5
Current: $3.28
Upside: +52.44%
Oct 1, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $21.92
Upside: -
Jan 3, 2018
Initiates: Outperform
Price Target: $22
Current: $1.63
Upside: +1,249.69%